Non-immunogenic recombinant staphylokinase versus alteplase for patients with massive pulmonary embolism: a randomized open-label, multicenter, parallel-group, non-inferiority trial, FORPE
Journal of Thrombosis and Haemostasis · 2025
DOI: 10.1016/j.jtha.2024.09.035 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025. Verfasst von Alexander I Kirienko und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Faculty Surgery, N.I. Pirogov Russian National Research Medical University, Moscow, Russia. Hauptthemen laut MEDLINE: Pulmonary Embolism, Tissue Plasminogen Activator, Fibrinolytic Agents, Thrombolytic Therapy. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Ministry of Science and Higher Education of the Russian Federation.
Abstract (Originalsprache)
BACKGROUND: Non-immunogenic staphylokinase is a modified recombinant staphylokinase with low immunogenicity, high thrombolytic activity, and fibrin selectivity. OBJECTIVES: To assess the safety and efficacy of a single intravenous bolus of non-immunogenic staphylokinase compared with those of alteplase in patients with massive pulmonary embolism and hemodynamic instability. METHODS: A randomized, open-label, multicenter, parallel-group, non-inferiority trial, the FORPE (FORtelyzin Pulmionary Embolism), was conducted in Russia. A total of 310 patients aged 18 years and older with computed tomography pulmonary angiography confirmed diagnosis of massive pulmonary embolism and right ventricular dysfunction were included. The patients were randomly assigned to receive either non-immunogenic staphylokinase (15 mg) or alteplase (100 mg), both administered intravenously. The primary efficacy endpoint was death from all causes within 7 days of randomization. RESULTS: A total of 155 patients were randomly assigned to receive non-immunogenic staphylokinase, and 155 received alteplase. In the non-immunogenic staphylokinase group, the primary efficacy endpoint was 2% in the intention-to-treat population, while in the alteplase group, it was 3% (odds ratio, 0.75; 95% CI, 0.11-4.49; P = 1.00). The difference in the primary efficacy endpoint was 0.6% (95% CI, -2.8% to 4.0%). Thus, the lower limit of the 95% CI did not cross the margin of non-inferiority. No cases of major bleeding were recorded in the non-immunogenic staphylokinase group, whereas there were 5 cases of major bleeding (3%; P = .09) in the alteplase group. CONCLUSION: Non-immunogenic staphylokinase was non-inferior to alteplase in patients with massive pulmonary embolism. Future observational studies are needed to assess its safety and efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Faculty Surgery, N.I. Pirogov Russian National Research Medical University, Moscow, Russia.
- Department of Faculty Surgery, N.I. Pirogov Russian National Research Medical University, Moscow, Russia. Electronic address: LeontievSG2024@yandex.ru.
- Department of Myocardial Diseases and Heart Failure, E.I. Chazov National Medical Research Center for Cardiology, Moscow, Russia.
- Department of Fundamental and Clinical Problems of Thrombosis in Non-infectious Diseases, National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russia.
- Department of Emergency Cardiology, E.I. Chazov National Medical Research Center for Cardiology, Moscow, Russia.
- Department of Faculty Therapy, N.I. Pirogov Russian National Research Medical University, Moscow, Russia.
Förderung
- Ministry of Science and Higher Education of the Russian Federation
Zitieren
APA
Kirienko, A. I., Leontyev, S. G., Tereschenko, S. N., Yavelov, I. S., Shakhnovich, R. M., Erlikh, A. D., Talibov, O. B., Yarovaya, E. B., Semenov, A. M., Semenov, M. P., Ivanov, S. V., Beregovykh, V. V., Archakov, A. I., Markin, S. S., & FORPE study group (2025). Non-immunogenic recombinant staphylokinase versus alteplase for patients with massive pulmonary embolism: a randomized open-label, multicenter, parallel-group, non-inferiority trial, FORPE. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2024.09.035
Vancouver
Kirienko AI, Leontyev SG, Tereschenko SN, Yavelov IS, Shakhnovich RM, Erlikh AD, et al. Non-immunogenic recombinant staphylokinase versus alteplase for patients with massive pulmonary embolism: a randomized open-label, multicenter, parallel-group, non-inferiority trial, FORPE. Journal of Thrombosis and Haemostasis. 2025. doi:10.1016/j.jtha.2024.09.035
BibTeX
@article{Kirienko2025,
author = {Kirienko, Alexander I and Leontyev, Stanislav G and Tereschenko, Sergey N and Yavelov, Igor S and Shakhnovich, Roman M and Erlikh, Alexey D and Talibov, Oleg B and Yarovaya, Elena B and Semenov, Andrey M and Semenov, Michail P and Ivanov, Sergey V and Beregovykh, Valery V and Archakov, Alexander I and Markin, Sergey S and FORPE study group, FORPE study group},
title = {Non-immunogenic recombinant staphylokinase versus alteplase for patients with massive pulmonary embolism: a randomized open-label, multicenter, parallel-group, non-inferiority trial, FORPE},
journal = {Journal of Thrombosis and Haemostasis},
year = {2025},
doi = {10.1016/j.jtha.2024.09.035}
}
EUVIMED